Transcatheter aortic valve implantation versus conservative treatment in chronic kidney disease patients

EuroIntervention 2018;14:e503-e510 published online April 2018 published online e-edition August 2018. DOI: 10.4244/EIJ-D-18-00058

Tali Steinmetz
Tali Steinmetz1,2*, MD; Guy Witberg1,3, MD; Avry Chagnac2,3, MD; Hefziba Green2,3, MD; Alexander Sagie1,3, MD; Benaya Rozen-Zvi2,3, MD; Ran Kornowski1,3, MD
1. Department of Cardiology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel; 2. Department of Nephrology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel; 3. “Sackler” School of Medicine, Tel Aviv University, Tel Aviv, Isr

Aims: There are no studies comparing transcatheter aortic valve implantation (TAVI) to conservative management in patients with chronic kidney disease stage 3-5 and severe aortic stenosis

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

aortic stenosisdeathrenal insufficiencytranscatheter aortic valve implantation
Interventions for valvular diseaseInterventions for heart failureTAVIChronic heart failureOther
Read next article
Computed tomography-based oversizing and incidence of paravalvular aortic regurgitation and permanent pacemaker implantation with a new-generation self-expanding transcatheter heart valve

Latest news